Lev Pavlovsky

39 Jabotinsky St, 4941492
Petah Tiqwa, M 49414, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Diagnosis and Treatment of Onychomycosis in Psoriasis Patients: A Single-Center Cohort Study.

Diagnosis and Treatment of Onychomycosis in Psoriasis Patients: A Single-Center Cohort Study.

Journal: Journal of cutaneous medicine and surgery

Published: July 24, 2026

Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study.

Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study.

Journal: Dermatology and therapy

Published: January 28, 2026

Systemic Biologic Treatment for Psoriasis in Elderly Patients.

Systemic Biologic Treatment for Psoriasis in Elderly Patients.

Journal: Journal of clinical medicine

Published: June 01, 2025

Bullous Pemphigoid as a Manifestation of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Report of a Novel Case.

Bullous Pemphigoid as a Manifestation of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Report of a Novel Case.

Journal: Journal of clinical medicine

Published: May 10, 2025

Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature.

Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature.

Journal: Archives of dermatological research

Published: February 26, 2025

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Journal: Dermatology and therapy

Published: January 17, 2025

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Journal: Dermatology and therapy

Published: August 16, 2024

Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors.

Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors.

Journal: Clinical and experimental dermatology

Published: April 03, 2024

Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.

Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.

Journal: Photodermatology, photoimmunology & photomedicine

Published: July 18, 2023

Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.

Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 23, 2023

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).

Journal: The British journal of dermatology

Published: June 12, 2023

Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review.

Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review.

Journal: American journal of clinical dermatology

Published: May 28, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026